• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 31, 2012

View Archived Issues

Tau-Targeting Approach Put to Test in TauRx's Phase III

LONDON – TauRx Therapeutics Ltd. said it has recruited the first patients to two Phase III Alzheimer's disease trials in which it aims to provide the first definitive proof that breaking down tangles of tau protein in the brain has a disease-modifying effect in the mild to moderate stages of pathology. Read More

Kymab Ramps Up Efforts for Antibody Partnerships, R&D

LONDON – Kymab Ltd. called up two industry veterans to help with the commercialization of its new platform technology for generating monoclonal antibodies in transgenic mice, as it prepares both to out-license access to the technology and use it to start an internal drug discovery effort. Read More

Vector-Triggered Innate Immune Activity Is Necessary for iPSCs

Researchers reported last week that the retroviral vector that is used for gene delivery in the generation of induced pluripotent stem cells, or iPSCs, does more than just ferry its cargo into cells. It activates the innate immune system – and that activation is critical for efficient reprogramming. Read More

CHDI's Global Network Aims To Tamp Down Huntington's

On a day when all eyes in the U.S. were trained on the path of destruction left by Hurricane Sandy, the CHDI Foundation Inc. was focused on a very different destroyer: Huntington's disease (HD). Read More

Financings Roundup

• Thesan Pharmaceuticals Inc., of San Diego, closed a $16 million Series A financing, co-led by Novo Ventures and Novartis Venture Funds. Read More

Other News To Note

• Complix NV, of Hasselt, Belgium, was awarded a grant of €1.9 million (US$2.4 million) from the Flanders government through the Agency for Innovation by Science and Technology in Flanders to speed up development of its cell penetrating alphabodies (CPABs) for a number of disease targets, including cancer. Read More

Clinic Roundup

• Ocular Therapeutix Inc., of Bedford, Mass., reported that a Phase II study of sustained-release travoprost (OTX-TP2) for glaucoma and ocular hypertension in 20 patients produced results comparable to topical brand name ophthalmic solutions travatan (Alcon Laboratories), Lumigan (Allergan Inc.) and Xalatan (Pfizer Inc.). Read More

Pharma: Other News To Note

• Sunovion Pharmaceuticals Inc., of Marlborough, Mass., said the FDA accepted for review two supplemental new drug applications for use of atypical antipsychotic Latuda (lurasidone) as monotherapy and as adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression). Read More

Washington Roundup

• A report by the Government Accountability Office (GAO) on Part D prices, called "Discount Program Effects and Brand-Name Drug Price Trends," found that prescription costs did not go up for other people on Medicare as a result of discounts given by pharma firms to the government as a way of closing the gap in benefits for senior citizens. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe